# Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

> **NCT03388632** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 31 (actual)

## Conditions studied

- Metastatic Solid Tumors
- Treatment-Refractory Cancers

## Interventions

- **DRUG:** rhIL-15
- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab
- **PROCEDURE:** Tumor biopsies
- **DIAGNOSTIC_TEST:** EKG
- **DIAGNOSTIC_TEST:** ECHO
- **DIAGNOSTIC_TEST:** CT Scan

## Key facts

- **NCT ID:** NCT03388632
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-05
- **Primary completion:** 2024-11-27
- **Final completion:** 2025-05-08
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03388632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03388632, "Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03388632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*